NCT07877753Completed
Evolution of Sickle Cell Maculopathy
Evolution of Vascular Defect in Macular Sickle Cell Maculopathy by OCT-A
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
To investigate retrospectively the longitudinal evolution of vascular defects in patients with typical or atypical forms of SCM.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 34 (actual)
- First submitted
- 6 Oct 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 20 Sept 2026
- Lead sponsor
- Christophe Orssaud
- Diseases
- Sickle cell disease
- NCT number
- NCT07877753
What you commit to
- Study type: Observational
- Participants enrolled: 34
- From 1 Sept 2026 to the primary completion date, 20 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Opposition that data were used for studies Poor OCT-A images quality
Who the study is looking for
- Sickle cell maculopathy on OCT-A At least two consultation
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Européen Georges Pompidou Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.